Using data from medical records and claims for 26 practices in the US Oncology Network, researchers found that cisplatin ...

Panelists discuss how axatilimab emerges as a promising later-line treatment option for patients with refractory or recurrent ...

During the 131st SLSWCA meeting held under chairmanship of Chief Secretary Manoj Ahuja, the investment plans across various ...

Committee for Medicinal Products for Human Use (CHMP) has recommended approving AstraZeneca’s Fasenra (benralizumab) to treat ...

Findings from the phase 3 SIERRA study showed that Iomab-B was associated with a higher durable complete response rate vs ...

Nevro noted that it expects to launch its full market release of HFX iQ with HFX AdaptivAI in the U.S. in the fourth quarter of 2024. For more information on HFX AdaptivAI, please visit ...

Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...

For patients with recurrent or refractory graft-versus-host disease (GVHD), the colony-stimulating factor 1 receptor ...

With FDA approval for imetelstat and solid financials, Geron shows great promise in MDS treatment. Read more on GERN stock ...

For patients with recurrent or refractory graft-versus-host disease (GVHD), the colony-stimulating factor 1 receptor ...

Annamycin demonstrated high uptake and retention in lung parenchyma of mice and rats. Annamycin is currently being evaluated in continuing clinical trials for the treatment of relapsed or refractory ...

CERATIZIT and PLANSEE to showcase refractory metal AM at Formnext presenting parts made of molybdenum, tungsten and cemented ...